No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
FRGE240517P2500
- 0.68
- -0.02-2.86%
15min DelayClose May 14 16:00 ET
0.70High0.68Low
0.70Open0.70Pre Close20 Volume111 Open Interest2.50Strike Price1.37KTurnover347.55%IV-3.19%PremiumMay 17, 2024Expiry Date0.62Intrinsic Value100Multiplier2DDays to Expiry0.06Time Value100Contract SizeAmericanOptions Type-0.7847Delta0.5138Gamma2.76Leverage Ratio-0.0297Theta-0.0001Rho-2.17Eff Leverage0.0005Vega
Intraday
- 5D
- 1D
News
Forge Global to Attend the J.P. Morgan 52nd Annual Global Technology, Media and Communications Conference
Forge Global Holdings, Inc. ("Forge," or the "Company") (NYSE:FRGE), a leading private securities marketplace, today announced that Mark Lee, Chief Financial Officer, and Dominic Paschel, SVP Finance and Investor
Forge Global Holdings, Inc. (NYSE:FRGE) Q1 2024 Earnings Call Transcript
Q1 2024 Forge Global Holdings Inc Earnings Call
Earnings Call Summary | Forge Global(FRGE.US) Q1 2024 Earnings Conference
The following is a summary of the Forge Global Holdings, Inc. (FRGE) Q1 2024 Earnings Call Transcript:Financial Performance:Forge Global Holdings reported Q1 2024 revenue of $19.2 million, up 2% from
Forge Global Holdings Inc (FRGE) (Q1 2024) Earnings Call Transcript Highlights: Navigating ...
JMP Securities Sticks to Its Buy Rating for Forge Global Holdings (FRGE)
Comments
Key Takeaway
GameStop ( $GameStop(GME.US$ ) and Forge Global ( $Forge Global(FRGE.US$ ) face pre-market declines of 17% and 11% respectively, while Novocure ( $Novocure(NVCR.US$ ) surges 30% on positive trial results.
Merck ( $Merck & Co(MRK.US$ ) gains 4% after FDA approval of its treatment, highlighting a day of significant volatility and strategic moves in the U.S. stock market.
A Glimpse into Quarter-End Moves
As the curtains draw near on...
GameStop ( $GameStop(GME.US$ ) and Forge Global ( $Forge Global(FRGE.US$ ) face pre-market declines of 17% and 11% respectively, while Novocure ( $Novocure(NVCR.US$ ) surges 30% on positive trial results.
Merck ( $Merck & Co(MRK.US$ ) gains 4% after FDA approval of its treatment, highlighting a day of significant volatility and strategic moves in the U.S. stock market.
A Glimpse into Quarter-End Moves
As the curtains draw near on...
1
Despite a dip in revenue, Forge Global Holdings' high P/S ratio indicates investors' anticipation of robust future growth. If analysts' predictions hold true, strong revenue forecasts could keep the share price afloat.
2
Gil Luria holds a neutral view on GitLab stock due to concerns about its valuation amid economic uncertainty. Despite demand stabilization, he worries about longer sales cycles and regards GitLab Duo's monetization as a company catalyst. He prefers JFrog due to its current valuations.
Insider share selling coupled with lack of buying and modest insider ownership signals caution for potential investors in the company.
$Forge Global(FRGE.US$ this could run to 6 to 7 easily.
I don’t believe though. But I’ll buy more at 2.
I don’t believe though. But I’ll buy more at 2.
Read more